Loading patent…
AssigneeKabushiki Kaisha Yakult Honsha
InventorsOsamu Matsuo, Masashi Sakai, Kisaku Shimura, Hiroshi Sansawa, Tsunekazu Watanabe, Tsuneo Matsumoto, Yoshiyuki Shishido, Shusuke Hashimoto, Teruo Yokokura, Masaharu Onoue, Tomoyuki Sako
Estimating the term…
A thrombolytic peptide composed of 136 amino acids residues, which has little problems of antigenicity and is efficacious in only small doses as compared with staphylokinase (SAK). This peptide is obtained by cleaving amino acids or peptides which do not affect the activity of SAK by using a trypsin protease. In particular, SAK-11, which is obtained by cleaving a peptide composed of ten amino acid residues at the N-terminal of SAK, is superior to SAK in the fibrinolysis, plasminogen activation, and fibrin specificity.
A thrombolytic agent comprising as its effective ingredient a peptide consisting of the amino acid sequence of SEQ ID NO:
A peptide having the amino acid sequence of sequence ID No:
A thrombolytic formulation comprising as an active ingredient an essentially pure thrombolytic peptide obtained by proteolytically removing ten N-terminal amino acid residues from staphlyokinase, the thrombolytic peptide having at least 50 percent higher plasminogen activation activity than staphylokinase, as measured by an absorbance test using plasma, a chromophore, and thrombin.
An essentially pure peptide produced by cleaving off and removing ten amino acid residues from the N-terminal end of staphylokinase.
A thrombolytic agent comprising as an active ingredient the peptide of claim 17.
Dependencies are inferred from the claim text.